Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
Trial Parameters
Brief Summary
This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Definite diagnosis of ACS; * Ability and willingness to provide written informed consent Exclusion Criteria: * Type 2 myocardial infarction (Patients with symptoms or signs of myocardial ischemia and evidence of increased oxygen demand or decreased supply \[for example, tachyarrhythmia, hypotension, or anaemia\] secondary to an alternative pathology and myocardial necrosis are defined as suffering type 2 myocardial infarction. The classification of type 2 myocardial infarction also includes patients with coronary vasospasm, embolism or spontaneous dissection without evidence of atherothrombosis related to coronary artery disease); * Valvular heart disease that is considered likely to require surgical intervention; * History of non-skin cancer in the past 3 years; * Inflammatory bowel disease or chronic diarrhea; * History of gastric ulcer or previous gastric bleeding; * Neuromuscular diseases or non-transient (At least 2 laboratory tests) creatin